


AMENDMENTS OF THE CLAIMS

The following **Listing of Claims**, in which deleted text appears as struck through or within bolded double brackets (e.g., **[[text]]**), and inserted text appears as underlined>, will replace all prior versions and listings of claims in the application. Text within single brackets stems for the original claims and should not be deleted.

Listing of Claims

Claim 1 (currently amended): A compound of the according to structural Formula I



wherein:

Q_a is phenyl, and Q_a may optionally bear 1 or 2 substituents R^a and R^b are each, independently of one another, selected from the group consisting of hydrogen, hydroxy, halogeno, trifluoromethyl, cyano, amino, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (1-6C)alkoxy, (1-6C)alkylamino, di-[(1-6C)alkyl]amino and (1-6C)alkoxycarbonyl;

R_1 and R_2 are each independently of one another selected from the group consisting of hydrogen, (1-6C)alkyl, (2-6C)alkenyl and (2-6C)alkynyl; and

Q_b is pyridyl, and Q_b may optionally bear 1 or 2 substituents R^c and R^d are each independently of one another, selected from the group consisting of hydrogen, hydroxy, halogeno, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl, (3-6C)cycloalkyl, (3-6C)cycloalkyl-(1-6C)alkyl, (1-6C)alkoxy, (3-6C)cycloalkoxy, (3-6C)cycloalkyl-(1-6C)alkoxy, carboxy, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, (1-6C)alkylamino-(1-6C)alkyl, di-[(1-6C)alkyl]amino-(1-6C)alkyl, (1-6C)alkylthio, (1-6C)alkylsulphonyl, (1-6C)alkylsulphonyl, aminosulphonyl, N-(1-6C)alkylsulphamoyl, N,N-di-[(1-6C)alkyl]sulphamoyl and (3-6C)cycloalkylsulphonyl;

and wherein any of the R^a, R^b, R^c and/or R^d substituents on Q_a or Q_b defined hereinbefore which comprise a CH₂ group attached to 2 carbon atoms or a CH₃ group attached to a carbon atom may optionally bear on each said CH₂ or CH₃ group that include a methylene or methyl group may optionally be substituted on said methylene or methyl group with one or more substituents independently selected from the group consisting of hydroxy, cyano, amino, (1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkylamino and di-[(1-6C)alkyl]amino;

or a pharmaceutically-acceptable salt thereof.

Claim 2 (currently amended): A compound of the Formula I according to **claim 1** wherein Q_a may optionally bear 1 or 2 substituents The compound or pharmaceutically acceptable salt of claim 1 in which R^a and R^b are each, independently of one another, selected from the group consisting of hydrogen, halogeno, (1-6C)alkyl and (1-6C)alkoxy; or a pharmaceutically acceptable salt thereof.

Claim 3 (currently amended): A compound of the Formula I according to **claim 1** wherein Q_a may optionally bear 1 or 2 substituents The compound or pharmaceutically acceptable salt of claim 1 in which the R^c and R^d are each, independently of one another, selected from the group consisting of hydrogen, hydroxy, halogeno, (1-6C)alkyl and (1-6C)alkoxy; or a pharmaceutically acceptable salt thereof.

Claims 4-6 (previously cancelled).

8 **Claim 7** (currently amended): A compound of the Formula I according to The compound or pharmaceutically acceptable salt of claim 1 or claim 2 wherein R₁ and R₂ are each independently of one another selected from the group consisting of hydrogen and (1-6C)alkyl; or a pharmaceutically acceptable salt thereof.

Claim 8 (previously cancelled).

Claim 9 (currently amended): A compound of the Formula I according to **claim 1** selected from the group consisting of:

N-cyclopropyl-4-methyl-3-{{[4-(pyridine-2-ylmethoxy)benzoyl]amino}benzamide;

N-cyclopropyl-4-methyl-3-{{[4-(pyridine-3-ylmethoxy)benzoyl]amino}benzamide;

N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-methoxy-4-(pyridin-2-ylmethoxy)benzamide;

N-cyclopropyl-4-methyl-3-{{[3-methyl-4-(pyridin-2-ylmethoxy)benzoyl]amino}benzamide;

N-(5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide; *N*-cyclopropyl-4-methyl-3-{{3-(pyridin-2-ylmethoxy)benzoyl}amino}benzamide; 3-chloro-*N*-(5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-4-(pyridin-2-ylmethoxy)benzamide; *N*-cyclopropyl-3-{{4-[(4-methoxypyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-4-methyl-3-{{4-(1-pyridin-2-ylethoxy)benzoyl}amino}benzamide; *N*-cyclopropyl-3-{{3-[(4-methoxypyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(5-(hydroxymethyl)pyridine-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(5-(1-hydroxy-1-methylethyl)pyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(5-[(isopropylamino)methyl]pyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(5-[(dimethylamino)methyl]pyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(5-[(cyclopropylamino)carbonyl]-2-methylphenyl)amino]carbonyl}phenoxy}methyl] nicotinate; *N*-cyclopropyl-3-{{4-[(5-[2-(dimethylamino)ethoxy]pyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(5-hydroxypyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(5-[(cyclopropylamino)carbonyl]-2-methylphenyl)amino]carbonyl}phenoxy}methyl] pyridine-2-carboxylate; *N*-cyclopropyl-3-{{4-[(6-(hydroxymethyl)pyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(6-(1-hydroxy-1-methylethyl)pyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(6-(2-diethylamino)ethoxy)methyl]pyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-cyclopropyl-3-{{4-[(6-[(2-dimethylamino)ethoxy)methyl]pyridin-2-yl)methoxy]benzoyl}amino}-4-methylbenzamide; *N*-(4-[(6-bromopyridin-2-yl)methoxy]benzoyl)amino)-*N*-cyclopropyl-4-methylbenzamide;

N-(5-[(cyclopropylamino)carbonyl]-2-methylphenyl)-3,5-difluoro-4-(pyridin-2-ylmethoxy)benzamide;
N-cyclopropyl-4-methyl-3-({4-[(6-methylpyridin-2-yl)methoxy]benzoyl}amino)benzamide;
N-cyclopropyl-4-methyl-3-({4-[(3-methylpyridin-2-yl)methoxy]benzoyl}amino)benzamide;
N-cyclopropyl-3-({[4-({6-[(2-methoxyethyl)amino]pyridin-2-yl}methoxy)benzoyl]amino}-4-methylbenzamide; and
N-cyclopropyl-3-({4-[(6-{[2-(dimethylamino)ethyl]amino}pyridin-2-yl)methoxy]benzoyl}amino)-4-methylbenzamide;

or a pharmaceutically-acceptable salt thereof.

Claim 10 (cancelled herein).

Claim 11 (currently amended): A pharmaceutical composition which comprises a compound of the Formula I as claimed in any one of claims 1, 2 and 9, or a pharmaceutically-acceptable salt thereof, in association with comprising a compound or pharmaceutically acceptable salt according to any one of claims 1, 2, 3, 7, 9, 17, 18, 19, 20, 21 and 22 and a pharmaceutically-acceptable diluent or carrier.

Claims 12-15 (previously cancelled).

Claim 16 (withdrawn and currently amended): A method for the treatment of rheumatoid arthritis, osteoarthritis, asthma, chronic obstructive pulmonary disease, inflammatory bowel disease, multiple sclerosis, AIDS, septic shock, congestive heart failure, ischaemic heart disease or psoriasis in a warm-blooded animal in need thereof treating arthritis comprising administering to said animal a subject suffering from arthritis an effective amount of a compound of the Formula I as claimed in any one of claims 1, 2 and 9, or a pharmaceutically-acceptable salt thereof or pharmaceutically acceptable salt according to any one of claims 1, 2, 3, 7, 9, 17, 18, 19, 20, 21 and 22.

Claim 17 (currently amended): The compound *N*-cyclopropyl-4-methyl-3-({[4-(pyridin-2-ylmethoxy)benzoyl]amino}benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 18 (currently amended): The compound *N*-cyclopropyl-4-methyl-3-({[4-(pyridin-3-ylmethoxy)benzoyl]amino}benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 19 (currently amended): The compound *N*-(5-(cyclopropylamino)carbonyl)-2-methylphenyl)-3-methoxy-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 20 (currently amended): ~~The compound~~ *N*-cyclopropyl-4-methyl-3-{[3-methyl-4-(pyridin-2-ylmethoxy)benzoyl]amino}benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 21 (currently amended): ~~The compound~~ *N*-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 22 (currently amended): ~~The compound~~ 3-chloro-*N*-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-4-(pyridin-2-ylmethoxy)benzamide, or a pharmaceutically-acceptable salt thereof.

Claim 23 (new): A method of treating arthritis comprising administering to a subject in need thereof an effective amount of a pharmaceutical composition according to **claim 16**.

Claim 24 (new): A method of inhibiting a p38 kinase, comprising contacting a p38 kinase with a compound or pharmaceutically acceptable salt according to **any one of claims 1, 2, 3, 7, 9, 17, 18, 19, 20, 21 and 22**.